Drugmakers Concerned About Supply Chain Regulations

A study carried out by global logistics firm UPS has revealed that regulatory issues top the list of supply chain concerns expressed by pharmaceutical companies. Among large pharmaceutical companies with sales topping US$1bn, 56% stated that an increased regulatory burden was their top concern, while approximately 30% of smaller drugmakers also attributed supply chain concerns to regulatory

To read the full article, please choose one of the following options: